JournalJournal of Alzheimer's Disease Reports
MetadataShow full item record
AbstractBackground: Current understanding of amyloid-β protein (Aβ) aggregation and toxicity provides an extensive list of drugs for treating Alzheimer's disease (AD); however, one of the most promising strategies for its treatment has been tri-peptides. Objective: The aim of this study is to examine those tri-peptides, such as Arg-Arg-Try (RRY), which have the potential of Aβ1-42 aggregating inhibition and Aβ clearance. Methods: In the present study, in silico, in vitro, and in vivo studies were integrated for screening tri-peptides binding to Aβ, then evaluating its inhibition of aggregation of Aβ, and finally its rescuing cognitive deficit. Results: In the in silico simulations, molecular docking and molecular dynamics determined that seven top-ranking tri-peptides could bind to Aβ1-42 and form stable complexes. Circular dichroism, ThT assay, and transmission electron microscope indicated the seven tri-peptides might inhibit the aggregation of Aβ1-42 in vitro. In the in vivo studies, Morris water maze, ELISA, and Diolistic staining were used, and data showed that RRY was capable of rescuing the Aβ1-42-induced cognitive deficit, reducing the Aβ1-42 load and increasing the dendritic spines in the transgenic mouse model. Conclusion: Such converging outcomes from three consecutive studies lead us to conclude that RRY is a preferred inhibitor of Aβ1-42 aggregation and treatment for Aβ-induced cognitive deficit.
Rights/Terms© 2021 – The authors. Published by IOS Press.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/16365
- Gallic acid disruption of Aβ<sub>1-42</sub> aggregation rescues cognitive decline of APP/PS1 double transgenic mouse.
- Authors: Yu M, Chen X, Liu J, Ma Q, Zhuo Z, Chen H, Zhou L, Yang S, Zheng L, Ning C, Xu J, Gao T, Hou ST
- Issue date: 2019 Apr
- 6-Methyluracil derivatives as acetylcholinesterase inhibitors for treatment of Alzheimer's disease.
- Authors: Zueva IV, Semenov VE, Mukhamedyarov MA, Lushchekina SV, Kharlamova AD, Petukhova EO, Mikhailov AS, Podyachev SN, Saifina LF, Petrov KA, Minnekhanova OA, Zobov VV, Nikolsky EE, Masson P, Reznik VS
- Issue date: 2015
- Silibinin inhibits acetylcholinesterase activity and amyloid β peptide aggregation: a dual-target drug for the treatment of Alzheimer's disease.
- Authors: Duan S, Guan X, Lin R, Liu X, Yan Y, Lin R, Zhang T, Chen X, Huang J, Sun X, Li Q, Fang S, Xu J, Yao Z, Gu H
- Issue date: 2015 May
- Effects of an amyloid-beta 1-42 oligomers antibody screened from a phage display library in APP/PS1 transgenic mice.
- Authors: Wang J, Li N, Ma J, Gu Z, Yu L, Fu X, Liu X, Wang J
- Issue date: 2016 Mar 15
- S14G-humanin inhibits Aβ1-42 fibril formation, disaggregates preformed fibrils, and protects against Aβ-induced cytotoxicity in vitro.
- Authors: Zhang W, Du Y, Bai M, Xi Y, Li Z, Miao J
- Issue date: 2013 Mar